Tag: $Eli Lilly

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial payment of about $6.3 billion in a deal that expands the drugmaker’s neuroscience portfolio and capabilities into sleep medicine.

Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ‌prices up to nearly 30% below its standard rate as it tries to widen access and regain ground from Eli Lilly in the booming obesity-drug market.

Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly’s (LLY) ‌Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the preparation, the U.S. drugmaker said in a public letter released on Thursday.

Eli Lilly (LLY) will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.

Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars.

Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.

Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry.

Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular ​obesity drug Zepbound to make the treatment more affordable for U.S. ‌patients, as demand for weight-loss therapies surge.

Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

Eli Lilly (LLY.N), said on Wednesday it is partnering with Walmart (WMT.N), to expand access to Lilly’s weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.

Eli Lilly and Novo Nordisk stocks fell sharply early Friday after President Donald Trump suggested the price of blockbuster weight-loss medicines could come down substantially.

Eli Lilly’s international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration’s new fast-track review process for its experimental weight-loss pill orforglipron.

Eli Lilly’s (LLY.N), blood cancer treatment Jaypirca helped patients live longer without the disease getting worse, the U.S. drugmaker said on Monday, meeting the main goal in a late-stage study in previously untreated patients.

Novo Nordisk’s (NOVO.B) Wegovy cut the risk of heart attacks, stroke and death by more than Eli Lilly’s (LLY) weight-loss drug Zepbound, a new study found.

Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to file for approval of the drug globally.

Eli Lilly(LLY) stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday.

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company’s older diabetes treatment, Trulicity.

 Eli Lilly (LLY.N), said on Thursday that India’s drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk’s recently launched Wegovy.

Shares in Novo Nordisk (NYSE:NVO) fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly (NYSE:LLY)’s pipeline.